Plain-English translation of NCT06051851 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a new immunotherapy medication called , when combined with two other anti-cancer drugs ( and a standard chemotherapy regimen), works better than chemotherapy alone for people with advanced pancreatic cancer that has spread to other parts of the body. About 177 people will participate across multiple hospitals. Half will receive the new combination treatment, and half will receive the standard chemotherapy alone, so doctors can compare how well each approach works.
Pancreatic cancer that has spread is very difficult to treat, and standard chemotherapy alone often doesn't work well enough. Researchers believe that adding an immunotherapy medication might help the body's immune system fight the cancer more effectively and help people live longer.
You will visit the hospital every three weeks for treatment cycles lasting 21 days each. During each cycle, you'll receive intravenous chemotherapy on days 1 and 8, and if you're in the treatment group, you'll also receive the immunotherapy medication on day 1 and take an oral medication () daily for 14 days. The study will check how well the treatment is working with scans and blood tests every 6 weeks for the first several months, then continue monitoring every 6 weeks. You'll continue treatment as long as it's helping and you can tolerate the side effects, which typically means several months or longer.
AI-generated summary from trial data Β· Jun 12, 2026 Β· Not medical advice
China